The first experience with thrombolytic therapy for cerebral infarction in the Russian Federation after the use of idarucizumab
| Autor: | N. N. Sukhacheva, E. V. Pudov, I. S. Petelina |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
specific antagonist Dabigatran Dysarthria idarucizumab Internal medicine Medicine dabigatran RC346-429 thrombolytic therapy business.industry Cerebral infarction Stroke scale Atrial fibrillation Idarucizumab medicine.disease Psychiatry and Mental health Clinical Psychology Hemiparesis Cardiology Russian federation Neurology. Diseases of the nervous system Neurology (clinical) medicine.symptom business medicine.drug |
| Zdroj: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 12, Iss 1, Pp 68-71 (2020) |
| ISSN: | 2310-1342 2074-2711 |
| Popis: | The paper describes a clinical case in which an 84-year-old patient with non-valvular atrial fibrillation (AF) who took dabigatran 110 mg twice a day developed recurrent ischemic stroke (IS) that caused dysarthria, left-sided hemiparesis, pain sensitivity and movement coordination impairments. At 170 minutes after IS development, idarucizumab was prescribed and thrombolytic therapy (TLT) was performed to neutralize the anticoagulant effect of dabigatran. At 24 hours after TLT, the National Institutes of Health Stroke Scale (NIHSS) scores were observed to decrease from 11 to 8; and repeated brain computed tomography revealed an ischemic focus in the left cerebellar hemisphere with hemorrhagic transformation to hemorrhagic heart attack type I. On day 19 of IS following the reversal of hemorrhagic transformation, dabigatran was resumed at a dose 110 mg twice a day. The described case, as well as other authors' data that reflect real clinical practice, confirms that the administration of idarucizumab is safe and allows TLT to be performed in patients with AF who develop IS while taking dabigatran. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|